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Abstract
Background: Because of the poor sensitivity of urinary cytological findings for the diagnosis of
especially low grade urinary bladder carcinoma, new molecular diagnostic methods have been
proposed. We decided to verify the ImmunoCyt/uCyt+ (UCyt+™) test and cytology combination
and cytokeratin 20 (CK20) and cytology combination in urine as possible diagnostic and monitoring
tool for bladder cancer.
Methods: Evaluation of CK20 expression and UCyt+™ was performed in urine of 90 patients of
which 54 with bladder cancer with primary/recurrent diagnosis (low grade urothelial carcinoma
(LGUC) = 23/8 patients, high grade urothelial carcinoma (HGUC) = 18/5 patients), and 36 patients
as control; except of neoplastic bladder disease patients. For the evaluation of the three tests,
CK20 and UCyt+™ tests were combined with urine cytology and compared with each other.
Results: The overall sensitivity detected for each tumor marker was as follows: for urine cytology
was 75.9% and UCyt+™ was 83.3%, for CK20 70.4%, while the specificity was 66.7% for urine
cytology and 86.1% for UCyt+™ and 83.3% for CK20. The sensitivity of cytology and UCyt+™
combination was higher (88.9%) than the sensitivity cytology and CK20 combination (77.8%). The
simultaneous use of the three markers, sensitivity was reaching 92.5%.
Conclusion: The UCyt+™ test and CK20 expression are valid tools for the performance of
adjunctive analyses with conventional cytologic examination.
Background
Bladder cancer is the second most common urologic can-
cer [1]. The majority of patients with newly diagnosed
bladder cancers have superficial, low-grade neoplasms
that are associated with an excellent prognosis. However,
these tumors have a 30% to 70% recurrence rate and may
progress to invasive cancers in 10% to 30% of patients;
progression greatly increases the risk of metastasis and
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subsequent mortality [2,3]. For this reason, the early
detection of bladder tumors is essential for improved
patient prognosis and long-term survival.
Cytology is noninvasive and has high specificity but low
sensitivity, especially for low-grade tumors. At the same
time, it can be a challenging test to perform and is highly
dependent on the skills and experience of a trained
cytopathologist. Thus, published studies have reported a
wide range of sensitivities (15.8%–84.6%) [4-12].
Because cystoscopy is invasive and because cytology has
poor sensitivity, noninvasive biomarkers have been
sought as alternatives to cystoscopy and cytology for the
detection and surveillance of bladder cancer.
The ImmunoCyt/uCyt+ (UCyt+™) test (Diagnocure) is an
immunocytological fluorescence assay designed to
improve the sensitivity of cytology. A cocktail of 3 mono-
clonal antibodies is used to detect antigens originating
specifically from tumors of transitional epithelial cells.
The M344 and LDQ10 antibodies are labeled with fluo-
rescein, a green fluorescence, and will recognize a mucin-
like antigen located in the urine on exfoliated tumor cells.
The 19A211 antibody will recognize the presence of a
high molecular weight glycosylated form of carcinoembri-
onic antigen and is labelled with Texas Red [13].
Still, this test, like cytology, remains subjective and
depends in part on the technician. Observer experience,
specimen stability and handling and differences in sample
size may explain the variation in reported UCyt+™ sensi-
tivity [6]. Because of this, we added another marker,
cytokeratin 20 (CK 20) which is easily used in conjunc-
tion with cytology and comparable with cytology and
UCyt+™ test.
Cytokeratins are intermediate filaments expressed in epi-
thelial cells [14]. One of these, cytokeratin 20, is expressed
higher in urothelial tumors in comparison with normal
transitional epithelium so it can be considered a marker of
urothelial differentiation [14].
The aim of this study was to investigate the validity of the
UCyt+™ test and CK20 expression alone and in combina-
tion with conventional cytology for detecting bladder can-
cer.
Methods
This study was performed on 90 patients admitted to the
Urology and Pathology Departments, Faculty of Medi-
cine, Erciyes University Hospitals, Turkey. All patients
provided a single voided urine sample, and cytological
tests of the urine sediment were performed before cystos-
copy. Cystoscopy was done for all patients as the reference
standard for identification of bladder cancer. All tumors
and suspicious lesions found were either resected or biop-
sied. The final diagnosis of bladder cancer was based on
histopathological examination.
To exclude interference with inflammation or hematuria,
none of the follow up urine samples was collected earlier
than 3 months after TUR-B or 1 month after intravesical
instillation.
For the cytologic examination 40 to 100 mL specimens of
voided urine were collected. This material was immedi-
ately fixed with equal volumes of 50% ethanol and 1 mL
of a special fixative solution. Samples were centrifuged at
2500 rpm for 10 minutes. Cytospin preparations 294
mm2 in diameter were prepared on poly-L-lysine-coated
slides. Slides were stained by a routine Papanicolaou
method and performed microscopic examination. The
slides were examined at 40× magnification.
All patients with superficial disease underwent transure-
thral resection of the bladder. Urothelial cancer grading
and staging were performed according to the World
Health Organization criteria [15].
On the cytologic examination, specimens were evaluated
for adequacy; those with fewer than 10 urothelial cells
were designated unsatisfactory and rejected. The primary
interpretation for each cytology case was classified as
benign or malignant by using previously published cyto-
logic criteria for the diagnosis of carcinoma [16]. Specifi-
cally, the cytologic parameters evaluated included
increased nuclear size elevated nuclear-to-cytoplasmic (N/
C) ratio, nuclear pleomorphism, hyperchromasia, nuclear
eccentricity, nuclear membrane irregularity, and cytoplas-
mic homogeneity. When none or one of these was
present, the diagnosis was rendered as "benign". When
most or all were present, the case was diagnosed as
"malignant". "Atypical or suspicious" cases were added to
the malignant group, which had two or three of these
parameters but were not sufficient for a "malignant" diag-
nosis. When calculating the sensitivity, specificity, posi-
tive and negative predictive values, the suspicious cases
were considered as positive cases.
The UCyt+™ is a commercially available immunocytolog-
ical assay based upon microscopical detection of tumor-
associated cellular antigens in urothelial cells by immun-
ofluorescence (Diagnocure Inc., Quebec, Canada). The
test was performed according to the manufacturer's proto-
col. Voided urine (>30 ml) was prefixed with an equal
amount of ethanol (50%) and 0.5 ml fixative solution.
The samples were then stored at 4°C for up to 7 days.
Slides with less than 500 nuclei or <1 epithelial cell/HPF
(200×) were excluded from the study. Positive and nega-
tive controls were performed with each test run. The sam-
ples were examined at 400× magnification. A sample wasDiagnostic Pathology 2009, 4:20 http://www.diagnosticpathology.org/content/4/1/20
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considered positive if one or more cells showed red and/
or green fluorescence. The test was negative if no red or
green fluorescent cells were detected.
Before immunocytochemistry for CK-20 was performed
using the standard streptavidin-biotin peroxidase com-
plex method, selected slides were decolorized with 0.5%
hydrochloric acid in 95% ethanol. Antigenic epitopes
were retrieved by way of a 15-minute incubation with 2%
3-amino-9-ethylcarbazole/1% hydrogen peroxidase/ace-
tate buffer. The slides were then placed in 3% hydrogen
peroxide/methanol for 20 minutes to block nonspecific
background staining due to endogenous peroxidase activ-
ity. The primary antibody CK-20 (clone Ks20.8, Neomar-
kers) was diluted 1:100 and applied to the slides for 30
minutes, followed by a 20-minute incubation in a second-
ary antibody (goat anti-mouse Ig) solution. Diaminoben-
zidine served as the chromagen and Mayer's hematoxylin
as the counterstain. The whole procedure was performed
at room temperature. An overall 5% of stained cells were
set as the threshold for a positive diagnosis.
The immunoreaction was topographically evaluated and
scored by the same pathologist. In accordance with previ-
ous reports, the CK20 staining pattern was considered
normal when an intense reaction was observed in the api-
cal cells, whereas diffuse or absent CK20 immunostaining
was considered an abnormal staining pattern.
The analysis of sensitivity, specificity as well as positive
and negative predictive values was performed evaluating
each test separately and the two and three together. Sensi-
tivity according to tumor grade was carried out for each
marker as well as the specificity and they were also evalu-
ated in the control group. Considering the three markers
together, the result was considered positive when at least
one marker was positively expressed and negative for
tumor diagnosis when all the markers were negative.
Results
Ninety patients included in the study, were diagnosed as
either the bladder cancer with primary/recurrent diagno-
sis or non-neoplastic bladder disease by histopathologic
examination. The malignant group consisted of 54
patients (mean age: 66, range 46–80 years) with urothe-
lial carcinoma [LGUC = 31 patients (23 primary/8 recur-
rent) and, HGUC = 23 patients (18 primary/5 recurrent)].
The control group consisted of 36 patients (mean age: 49,
range 30–78 years), which were non-neoplastic bladder
disease patients with cystitis (n = 9), glomerular disease (n
= 6) and as individuals with benign prostatic hyperplasia
(n = 11), or patients with a history of prostate cancer (n =
5) and renal cell carcinoma patients (n = 5).
The primary interpretation for each cytology case was clas-
sified as benign (n = 37) or malignant (n = 53). "Atypical
or suspicious" cases (n = 14) were added to the malignant
group. In control group, of the 36 analyses with no tumor
present, cytology was negative in 24 patients and, there-
fore, the specificity was 66.7% (Table 1). Of the 54 cases
in which a tumor was present, cytology were positive in 41
cases, and the sensitivity of cytology was 75.9%. On the
other hand; of the 54 cases for which a tumor was present,
45 were positive by UCyt+™ and the sensitivity was 83.3%
(Table 1). In the control group, 31 were negative by
UCyt+™ and the specificity was 86.1%. Immunocytology
with CK20 had a sensitivity of 70.4% and a specificity of
83.3% (Table 1).
The results of UCyt+™ and CK20 expression were com-
pared with urine cytology (Table 1). The sensitivity for the
UCyt+™ test was 83.3%, urine cytology 75.9% and CK20
70.3%. The combination of UCyt+™ and cytology, CK20
and cytology, and the three tests together showed sensitiv-
ities of 88.9%, 77.7%, and 92.5% respectively.
As reported in Table 2, the sensitivity is higher for UCyt+™
and cytology than for CK20 in low grade tumors: 77.4%,
67.7% and 64.5%, respectively (Figure 1). In high grade
tumors the sensitivity for UCyt+™ was 91.3%, 86.9% for
cytology, and 78.2% for CK20 (Figure 2). The combina-
tion of UCyt+™ and cytology had higher sensitivity
(83.8%) than the CK20 and cytology combination
(70.9%). From the simultaneous evaluation of the three
tumor markers, 90.3% of the diagnoses were correct
(Table 2).
Discussion
The urine cytology is a useful test in both diagnosis and
follow-up and is highly sensitive for detecting high grade
tumors; it is limited because of the decreased sensitivity in
detecting low-grade tumors. A recent literature review
found that the sensitivity of cytology is between 20% to
53%, with a mean of 34%; specificity ranges from 83% to
99.7%, with a mean of 99% [17,18]. Additional screening
tests with high sensitivity for tumors of all grades are
needed to improve the diagnostic ability of urine cytology
and perhaps to reduce the need for frequent cystoscopies,
especially in those with low-risk disease.
During the past decade, more than 30 urinary bladder
cancer biomarkers have been described [19]. Among
these, bladder tumor antigen (BTA Stat and BTA TRAK
tests), nuclear matrix protein 22 (NMP-22 enzyme linked
immunosorbent assay detection kit) and recently tumor-
associated antigens such as M344, 19A211, and LDQ19
(ImmunoCyt fluorescence test), fibrinogen-fibrin degra-
dation products (FDP test), and the UroVysion fluores-
cent in situ hybridization assay have achieved Food and
Drug Administration approval for diagnostic purposes.
Still, most of the aforementioned tests are less specific and
cost more than conventional cytology [20]. Several largeDiagnostic Pathology 2009, 4:20 http://www.diagnosticpathology.org/content/4/1/20
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screening studies have demonstrated its low sensitivity
and the results of urinary cytology have poor interob-
server and intraobserver reproducibility [21].
Halling et al [22] noted that for grade 1, grade 2 and grade
3 bladder tumours, respectively, the grade per grade sensi-
tivity of cytology before 1990 was 37%, 75% and 94%
and that it decreased to 11%, 31% and 60% after 1990.
The suspected reason for the drop in sensitivity is that,
before 1990, studies were conducted by pathologists with
great expertise in the field of urine cytology, whereas more
recently, cytology has become one of many tests per-
formed by general pathologists lacking direct expertise in
urine cytology. In our institute cytologic examination is
performed by a trained cytopathologist.
Table 1: Sensitivity, specificity, and positive (PPV) and negative predictive value (NPV) for cytology, ImmunoCyt/uCyt+, CK20 and 
combinations.





Negative Sensitivity Specificity PPV NPV OA
Cytology + 21 20 12 75.9 66.7 77.3 88.9 72.2
-1 0 3 2 4
UCyt+™ + 24 21 5 83.3 86.1 90.0 79.5 84.4
-7 2 3 1
CK20 + 20 18 6 70.4 83.3 86.3 65.2 75.5
-1 1 5 3 0
Cytology+ UCyt+™ + 26 22 5 88.9 86.1 90.5 86.1 87.7
-5 1 3 1
Cytology+ CK20 + 22 20 12 77.8 66.7 77.7 66.7 73.3
-9 3 2 4
UCyt+™+ CK20 + 23 21 7 81.5 80.5 86.3 74.3 81.1
-8 2 2 9
Cytology+ UCyt+™ + CK20 + 28 22 12 92.5 66.7 80.6 85.7 82.2
-3 1 2 4
+: Positive test result, -: Negative test result Negative: Negative for malignancy PPV:Positive predictive value NPV: Negative predictive value OA: 
Overall accuracy
Table 2: Comparison of cytology, ImmunoCyt/uCyt+ and CK20 
expression for the detection of different grades of bladder 
cancer
Urothelial tumors
Low grade High grade
n = 31 % n = 23 %
Cytology 21 67.7 20 86.9
UCyt+™ 24 77.4 21 91.3
CK20 20 64.5 18 78.2
Cytology+UCyt+™ 26 83.8 22 95.6
Cytology+CK20 22 70.9 20 86.9
UCyt+™ +CK20 23 74.1 21 91.3
Cytology+UCyt+™ +CK20 28 90.3 22 95.6
[A] Low grade urothelial carcinoma cytology (Papanicolaou  stain ×200), [B] Positive Immunocyt/uCyt test (red fluores- cence × 200), [C] CK20 immunocytochemistry (×200), [D]  Biopsy (HE × 200) Figure 1
[A] Low grade urothelial carcinoma cytology 
(Papanicolaou stain ×200), [B] Positive Immunocyt/
uCyt test (red fluorescence × 200), [C] CK20 immu-
nocytochemistry (×200), [D] Biopsy (HE × 200).Diagnostic Pathology 2009, 4:20 http://www.diagnosticpathology.org/content/4/1/20
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Unlike other urinary markers, UCyt+™ and CK20 are not
approved as a stand-alone test but rather, are only
approved for use as a surveillance test in conjunction with
cytology, which makes direct comparison with other
markers more difficult. Overall sensitivity of the com-
bined UCyt+™ and cytology assay has been reported in the
range of 81.0%–94.1% [23,24]. Specificity of the com-
bined assay reaches to 61.0%–77.7%, which is less than
that offered by cytology alone [24,25]. In our study the
sensitivity for cytology is 75.9% and for UCyt+™ is 83.3%
and for combination of the both tests are 88.9%. In low
grade tumors the sensitivity for UCyt+™ (77.4%) is more
than for cytology (67.7%) and for the combination of
both tests (83.8%). On the other hand the specificity for
cytology (66.7%) reached 86.1% for the combination of
the two tests (Table 1). These results are in parallel with
most of the reports [11,24].
In our study the CK20 sensitivity is 70.4% and less than
for cytology and UCyt+™, but reached 77.8% when com-
bined with urine cytology. Some authors reported sensi-
tivity for CK20 between 86% and 91% with a specificity
between 67% and 96% even if in most of the cases the
specificity was tested in healthy controls and not in urine
from cases of chronic inflammation [25,26]. In these
series strong correlation was found between tumor grade
and CK20 expression in urine. The sensitivity was higher
for CK20 than urine cytology. According to a recently pub-
lished article the sensitivity of CK20 mRNA was 100% in
detecting grade 1 tumors, whereas the sensitivity for high
grade (III) was 84.3%. This suggests that CK20 mRNA is a
potential tumor marker for the early detection of bladder
cancer [27]. In our study we could not find any relation
between tumor grade and CK20 expression.
Cytology and cystoscopy have been used as detection tests
for patients suspicious for bladder cancer or for the sur-
veillance of patients at risk of tumor recurrence. Cystos-
copy is highly sensitive for most tumors but has some
practical limitations. It may fail to identify smaller, flat
tumors such as carcinoma in situ. Also, despite the techni-
cal advances in cystoscopes, the procedure is often per-
ceived as invasive and a source of patient anxiety [28].
There is also a significant financial cost related to frequent
cystoscopic monitoring, in terms of health care resources
and patient time. Conversely, urinary cytology is noninva-
sive and highly specific but has poor sensitivity for low-
grade, well-differentiated lesions. Thus it cannot be used
to replace cystocopy and is used, rather, as an adjunct to
help detect occult tumors. Additional screening tests with
high sensitivity and specificity for urothelial tumors of all
grades are indicated to help improve the diagnostic ability
of urine cytology as well as to reduce the need for frequent
cystoscopies, especially in those with low-risk disease.
The ImmunoCyt/uCyt+ assay require technical expertise,
extensive sample handling and preparation and special-
ized equipment. However, a person with minimal cytol-
ogy training and experience can perform the test. The
CK20 immunostaining can be used routinely but needs
some additional work performed by the technician
(bleaching of slides etc).
Conclusion
In conclusion, combined use of UCyt+™ and cytology can
improve the sensitivity and specificity over the CK20 and
cytology combination for the detection of bladder cancer
in urine. Further new studies with larger patient popula-
tions should be done in order to assess the effectiveness of
these tests to replace conventional cystoscopy in the pri-
mary diagnosis.
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[A] High grade urothelial carcinoma cytology (Papanicolaou  stain × 200), [B] Positive Immunocyt/uCyt test (red fluores- cence× 200), [C] CK20 immunocytochemistry (×200) Figure 2
[A] High grade urothelial carcinoma cytology 
(Papanicolaou stain × 200), [B] Positive Immunocyt/
uCyt test (red fluorescence × 200), [C] CK20 immu-
nocytochemistry (×200), [D] Biopsy (HE × 200).Publish with BioMed Central    and   every 
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